Neurodegenerative Disease Treatment Market – The main driver of market growth is a strong drug pipeline; CMI reveals prospects until 2026
The Neurodegenerative Disease Treatment market report includes historical data, current market trends, environment, technological innovation, upcoming technologies, and technical advancements in the related industry. Neurodegenerative Disease Treatment Market offers a comprehensive and proficient report providing relevant market research data for new market entrants or establishment players. The key strategies of the companies operating in the market and their impact analysis have been included in the report.
Neurodegenerative diseases involve a progressive loss of the function and structure of neurons, which sometimes also includes the death of neurons. It includes a range of conditions typically affecting neurons in the human brain. It is mainly due to a toxic protein substance in the brain, which hinders the functioning of the mitochondria in the brain. Some of the neurodegenerative diseases are caused by genetic mutations due to the expansion of the CAG trinucleotide and the poly Q tract, for example, Huntington’s disease and spinocerebellar ataxias. Some neurodegenerative diseases are caused by the aggregation of misfolded proteins, for example Alzheimer’s disease, Huntington’s disease and Parkinson’s disease. One of the common factors of cell death in neurodegeneration is the intrinsic mitochondrial apoptotic pathway, eg amyotrophic lateral sclerosis. Alzheimer’s disease is caused by the aggregation of misfolded proteins. Parkinson’s disease affects the central nervous system by an abnormal buildup of ubiquitin-bound alpha-synuclein protein in damaged cells. Huntington’s disease is a genetic disease that causes the breakdown of nerve cells in the brain.
Get Your FREE Sample of Neurodegenerative Disease Treatment Market 2021 Report
Market dynamics – Factors
The availability of a strong pipeline of drugs indicated for neurodegenerative disorders is expected to drive the growth of the global market neurodegenerative disease treatment market during the forecast period. For example, in 2017 FlorbetapirF 18, sponsored by Avid Radiopharmaceuticals, a pharmaceutical company focused on improving clinical drug development, completed phase 2 clinical trials. This drug is used as a biomarker for neurodegenerative diseases such as dementia. ‘Alzheimer’s. Washington School of Medicine sponsored F 18 T807 has been in phase 2 clinical trials since 2015. This drug is used to treat amyotrophic lateral sclerosis (ALS).
Moreover, the major market players are involved in mergers and acquisitions, which in turn are expected to drive the market growth in the near future. For example, in June 2018, Alexion Pharmaceuticals Inc., a global biopharmaceutical company based in the United States, merged with Complement Pharma, a biotechnology company based in the Netherlands, to develop the preclinical complement inhibitor C-6 CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). Inhibition of C6 prevents the formation of the membrane attack complex (MAC), a complex of terminal complement proteins, which has the potential to treat a variety of central nervous system disorders.
The high prevalence of neurodegenerative diseases and the launch of new products are expected to propel the global neurodegenerative disease treatment market during the forecast period. For example, in 2018, ArunA Biomedical launched a biological exosome (vesicles derived from cells found in the blood) to treat the central nervous system (CNS) and neurodegenerative diseases. The biologics of exosomes are used in the treatment of CNS and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Buy this premium report now to grow your business: https://www.coherentmarketinsights.com/insight/buy-now/1860
Reasons to buy this report
• Current and future outlook for the global neurodegenerative disease treatment market in developed and emerging markets.
• The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
• Regions / countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies used by the main market players
“Limited time offer”
Access an in-depth study with over 150 pages, a list of tables and figures, profiling over 20 companies.
We also offer 15% FREE customization of reports.
Get this premium report with an instant discount of US $ 2000 @ https://www.coherentmarketinsights.com/promo/buynow/1860
Increasing research on the treatment of neurodegenerative diseases is expected to drive the growth of the global neurodegenerative disease treatment market. For example, E-Scape Bio, a biopharmaceutical company, would invest more than US $ 63 million in research for the treatment of Parkinson’s and Alzheimer’s disease from 2017 for the development of a new drug.
Market dynamics – Constraints
Lack of reimbursement policies by government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) is expected to dampen the growth of the global treatment market. neurodegenerative diseases in the near future.
Among the regions, North America is expected to dominate the global neurodegenerative disease treatment market during the forecast period. This is due to strategic mergers and acquisitions between the main players. For example, in 2018, Abbvie Inc., a biopharmaceutical company, merged with Voyager Therapeutics, a gene therapy development company to develop gene therapies to treat Alzheimer’s disease. In 2014 Bristol Myers Squibb, a US pharmaceutical company acquired iPierian Inc., a drug discovery platform that develops therapies for neurodegenerative diseases. Bristol Myers Squibb has acquired IPN007, iPierian’s leading drug. IPN007 is a monoclonal antibody used to treat progressive supranuclear palsy (a medical condition characterized by deterioration of cells in various areas of the brain that control thinking and movement of the body).
In addition, the European Neurodegenerative Disease Treatment market is expected to experience significant growth, owing to the increasing prevalence of Neurodegenerative Diseases in the region. According to a survey conducted by the Parkinson Association of the Carolinas in 2016, more than 60,000 new people in the United States are diagnosed with Parkinson’s disease each year. Hence, the increasing number of neurodegenerative diseases in turn is driving the growth of the neurodegenerative disease treatment market in Europe.
Request Sample PDF Copy of Neurodegenerative Disease Treatment Market Report @ https://www.coherentmarketinsights.com/insight/request-sample/1860
The major players operating in the global neurodegenerative disease treatment market include Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, CH Boehringer Sohn AG & Co. KG, Sanofi SA, GlaxoSmithKline and Neuro-Hitech Inc.
Global Taxonomy of Neurodegenerative Disease Treatment Market: –
By drug class: –
- NMDA receiver
- Dopamine inhibitors
- Cholinesterase inhibitors
- SSRI inhibitor
By disease: –
- Parkinson’s disease
- Huntington’s disease
- Alzheimer’s disease
- Amyotrophic lateral sclerosis
By distribution channel: –
- Online pharmacies
- Retail pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
The main points covered in the Neurodegenerative Disease Treatment market research are as follows: –
• What will be the Growth Rate, Overview, and Analysis of the Market by Type of Neurodegenerative Disease Treatment Market in 2026?
• What are the key factors driving, analysis by applications and countries the Neurodegenerative Disease Treatment market?
• What is dynamics, this overview comprises scope analysis and price analysis of key manufacturer profiles of the Neurodegenerative Disease Treatment Market?
• Who are the opportunities, risks, and driving force behind the Neurodegenerative Disease Treatment market? Knows the upstream raw material supply and downstream buyers
• Who are the major vendors in the neurodegenerative disease treatment market? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Neurodegenerative Disease Treatment Market opportunities and threats faced by the vendors in the market?
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients of all backgrounds, from Fortune 500 companies to nonprofits and startups looking to enter the market. We excel in delivering unmatched actionable market insights across a variety of industry verticals including Chemicals & Materials, Healthcare, Food & Beverage, Consumer Goods, Packaging, Semiconductors , software and services, telecommunications and automotive. We offer syndicated market intelligence reports, custom research solutions, and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837